These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34908838)

  • 21. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.
    Citrome L
    Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):193-206. PubMed ID: 23320989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.
    Lao KS; He Y; Wong IC; Besag FM; Chan EW
    CNS Drugs; 2016 Nov; 30(11):1043-1054. PubMed ID: 27550371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mini Review on Cariprazine: A Promising Antipsychotic Agent.
    Patel A; Patel A; Patel D; Patel K; Bambharoliya T
    CNS Neurol Disord Drug Targets; 2023; 22(2):226-236. PubMed ID: 35331126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2019 Oct; 73(10):e13397. PubMed ID: 31355510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
    Gründer G
    Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia.
    Riccobene T; Riesenberg R; Yeung PP; Earley WR; Hankinson AL
    J Child Adolesc Psychopharmacol; 2022 Oct; 32(8):434-443. PubMed ID: 36282772
    [No Abstract]   [Full Text] [Related]  

  • 27. The Role of Dopamine D
    Huang M; He W; Kiss B; Farkas B; Adham N; Meltzer HY
    J Pharmacol Exp Ther; 2019 Nov; 371(2):517-525. PubMed ID: 31511365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cariprazine on Psychosis: Beyond Schizophrenia - A Case Series.
    Bajouco M; Mota D
    Neuropsychiatr Dis Treat; 2022; 18():1351-1362. PubMed ID: 35818373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety.
    Laszlovszky I; Barabássy Á; Németh G
    Adv Ther; 2021 Jul; 38(7):3652-3673. PubMed ID: 34091867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cariprazine: A new partial dopamine agonist with a familiar profile.
    Hope J; Keks NA
    Australas Psychiatry; 2022 Jun; 30(3):382-385. PubMed ID: 35156402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cariprazine in Pediatric Patients with Autism Spectrum Disorder: Results of a Pharmacokinetic, Safety and Tolerability Study.
    Yeung PP; Johnson KA; Riesenberg R; Orejudos A; Riccobene T; Kalluri HV; Malik PR; Varughese S; Findling RL
    J Child Adolesc Psychopharmacol; 2023 Aug; 33(6):232-242. PubMed ID: 37437109
    [No Abstract]   [Full Text] [Related]  

  • 32. The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders.
    De Berardis D; Orsolini L; Iasevoli F; Prinzivalli E; de Bartolomeis A; Serroni N; Mazza M; Valchera A; Fornaro M; Vecchiotti R; Carano A; Sepede G; Vellante F; Matarazzo I; Pompili M; Perna G; Conti C; Segura-García C; Martinotti G; Di Giannantonio M
    Curr Pharm Des; 2016; 22(33):5144-5162. PubMed ID: 27396597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cariprazine:New dopamine biased agonist for neuropsychiatric disorders.
    De Deurwaerdère P
    Drugs Today (Barc); 2016 Feb; 52(2):97-110. PubMed ID: 27092339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study.
    Earley W; Burgess MV; Rekeda L; Dickinson R; Szatmári B; Németh G; McIntyre RS; Sachs GS; Yatham LN
    Am J Psychiatry; 2019 Jun; 176(6):439-448. PubMed ID: 30845817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases.
    Berardis D; Rapini G; Olivieri L; Giardini A; Lauretis I; Serroni N; Orsolini L; Fornaro M; Iasevoli F; Trotta S; Cottura P; Vellante F; Alessandrini M; Giannantonio MD
    Clin Psychopharmacol Neurosci; 2021 Feb; 19(1):174-178. PubMed ID: 33508803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine.
    Batinic B; Ristic I; Zugic M; Baldwin DS
    Front Psychiatry; 2021; 12():784370. PubMed ID: 34887792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Involvement of 5-HT
    Herman A; El Mansari M; Adham N; Kiss B; Farkas B; Blier P
    Mol Pharmacol; 2018 Dec; 94(6):1363-1370. PubMed ID: 30322874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine D3 Receptors: From Bench to Bedside.
    Gonda X; Tarazi FI
    Neuropsychopharmacol Hung; 2021 Jun; 23(2):272-280. PubMed ID: 34342419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cariprazine for Schizophrenia and Bipolar Disorder.
    Scarff JR
    Innov Clin Neurosci; 2016; 13(9-10):49-52. PubMed ID: 27975000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of cariprazine in the treatment of bipolar disorder.
    Saraf G; Pinto JV; Yatham LN
    Expert Opin Pharmacother; 2019 Dec; 20(17):2063-2072. PubMed ID: 31644326
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.